Digitisation | December 17, 2021
Alloy Therapeutics acquires deepCDR Biologics to bring ML into drug discovery
The deepCDR engine combines deep sequencing and deep learning methods with a proprietary mammalian display process to select from a wide range of antibodies and rapidly identify candidates with the highest possible affinity and developability profiles
